Knight, J. S. et al. The intersection of COVID-19 and autoimmunity. J. Clin. Invest. 131, e154886 (2021).
Galeotti, C. & Bayry, J. Autoimmune and inflammatory diseases following COVID-19. Nat. Rev. Rheumatol. 16, 413–414 (2020).
Merad, M., Blish, C. A., Sallusto, F. & Iwasaki, A. The immunology and immunopathology of COVID-19. Science 375, 1122–1127 (2022).
Gregorova, M. et al. Post-acute COVID-19 associated with evidence of bystander T-cell activation and a recurring antibiotic-resistant bacterial pneumonia. Elife 9, 1–13 (2020).
Karami Fath, M. et al. SARS-CoV-2 proteome harbors peptides which are able to trigger autoimmunity responses: implications for infection, vaccination, and population coverage. Front. Immunol. 12, 3174 (2021).
Vojdani, A., Vojdani, E. & Kharrazian, D. Reaction of human monoclonal antibodies to SARS-CoV-2 proteins with tissue antigens: implications for autoimmune diseases. Front. Immunol. 11, 617089 (2021).
Vojdani, A. & Kharrazian, D. Potential antigenic cross-reactivity between SARS-CoV-2 and human tissue with a possible link to an increase in autoimmune diseases. Clin. Immunol. 217, 108480 (2020).
Nunez-Castilla, J. et al. Potential autoimmunity resulting from molecular mimicry between SARS-CoV-2 spike and human proteins. Viruses 14, 1415 (2022).
Aschman, T. et al. Association between SARS-CoV-2 infection and immune-mediated myopathy in patients who have died. JAMA Neurol. 78, 948–960 (2021).
Li, Y. et al. Acute cerebrovascular disease following COVID-19: a single center, retrospective, observational study. Stroke Vasc. Neurol. 5, 279–284 (2020).
Moll, G. et al. MSC therapies for COVID-19: importance of patient coagulopathy, thromboprophylaxis, cell product quality and mode of delivery for treatment safety and efficacy. Front. Immunol. 11, 1091 (2020).
Libby, P. & Lüscher, T. COVID-19 is, in the end, an endothelial disease. Eur. Heart J. 41, 3038–3044 (2020).
Rojas, M. et al. Autoimmunity is a hallmark of post-COVID syndrome. J. Transl. Med. 20, 1–5 (2022).
Davis, H. E. et al. Characterizing long COVID in an international cohort: 7 months of symptoms and their impact. EClinicalMedicine 38, 101019 (2021).
Spudich, S. & Nath, A. Nervous system consequences of COVID-19. Science. 375, 267–269 (2022).
Xu, E., Xie, Y. & Al-Aly, Z. Long-term neurologic outcomes of COVID-19. Nat. Med. https://doi.org/10.1038/s41591-022-02001-z (2022).
Mehandru, S. & Merad, M. Pathological sequelae of long-haul COVID. Nat. Immunol. 2022 232 23, 194–202 (2022).
Bastard, P. et al. Autoantibodies against type I IFNs in patients with life-threatening COVID-19. Science 370, eabd4585 (2020).
Wang, E. Y. et al. Diverse functional autoantibodies in patients with COVID-19. Nature 595, 283–288 (2021).
Fagyas, M. et al. The majority of severe COVID-19 patients develop anti-cardiac autoantibodies. GeroScience https://doi.org/10.1007/S11357-022-00649-6 (2022).
Zuo, Y. et al. Prothrombotic autoantibodies in serum from patients hospitalized with COVID-19. Sci. Transl. Med. 12, 3876 (2020).
Zuniga, M. et al. Autoimmunity to the lung protective phospholipid-binding protein annexin A2 predicts mortality among hospitalized COVID-19 patients. medRxiv https://doi.org/10.1101/2020.12.28.20248807 (2021).
ClinicalTrials.gov. Losartan for Patients With COVID-19 Requiring Hospitalization. https://classic.clinicaltrials.gov/ct2/show/NCT04311177 (2021).
Cavalli, E. et al. Entangling COVID-19 associated thrombosis into a secondary antiphospholipid antibody syndrome: Diagnostic and therapeutic perspectives (Review). Int. J. Mol. Med. 46, 903–912 (2020).
Dotan, A. et al. The SARS-CoV-2 as an instrumental trigger of autoimmunity. Autoimmun. Rev. 20, 102792 (2021).
Trahtemberg, U. et al. Anticardiolipin and other antiphospholipid antibodies in critically ill COVID-19 positive and negative patients. Ann. Rheum. Dis. 80, 1236–1240 (2021).
Juanes-Velasco, P. et al. SARS-CoV-2 infection triggers auto-immune response in ARDS. Front. Immunol. 13, 1–13 (2022).
Chang, S. et al. New-onset IgG autoantibodies in hospitalized patients with COVID-19. Nat. Commun. 12, 5417 (2021).
Woodruff, M. C. et al. Relaxed peripheral tolerance drives broad de novo autoreactivity in severe COVID-19. medRxiv https://doi.org/10.1101/2020.10.21.20216192 (2021).
Taeschler, P. et al. Autoantibodies in COVID-19 correlate with antiviral humoral responses and distinct immune signatures. Allergy 77, 2415–2430 (2022).
Baiocchi, G. C. et al. Autoantibodies linked to autoimmune diseases associate with COVID-19 outcomes. medRxiv https://doi.org/10.1101/2022.02.17.22271057 (2022).
Liu, Y. et al. Association between age and clinical characteristics and outcomes of COVID-19. Eur. Respir. J. 55, 2001112 (2020).
Davies, N. G. et al. Age-dependent effects in the transmission and control of COVID-19 epidemics. Nat. Med. 26, 1205–1211 (2020).
Team, F. Variation in the COVID-19 infection–fatality ratio by age, time, and geography during the pre-vaccine era: a systematic analysis. Lancet 399, 1469–1488 (2022).
Ma, S., Wang, C., Mao, X. & Hao, Y. R Cells dysfunction associated with aging and autoimmune disease. Front. Immunol. 10, 318 (2019).
López-Otín, C., Blasco, M. A., Partridge, L., Serrano, M. & Kroemer, G. The hallmarks of aging. Cell 153, 1194 (2013).
Chalan, P., Berg, A., van den, Kroesen, B.-J., Brouwer, L. & Boots, A. Rheumatoid arthritis, immunosenescence and the hallmarks of aging. Curr. Aging Sci. 8, 131 (2015).
Wang, Y. et al. Cytoplasmic DNA sensing by KU complex in aged CD4+ T cell potentiates T cell activation and aging-related autoimmune inflammation. Immunity 54, 632–647.e9 (2021).
Barbé-Tuana, F., Funchal, G., Schmitz, C. R. R., Maurmann, R. M. & Bauer, M. E. The interplay between immunosenescence and age-related diseases. Semin. Immunopathol. 42, 545–557 (2020).
Arvey, A. et al. Age-associated changes in the circulating human antibody repertoire are upregulated in autoimmunity. Immun. Ageing 17, 1–16 (2020).
Andrzejewska, A. et al. Multi-parameter analysis of biobanked human bone marrow stromal cells shows little influence for donor age and mild comorbidities on phenotypic and functional properties. Front. Immunol. 10, 2474 (2019).
Shome, M. et al. Serum autoantibodyome reveals that healthy individuals share common autoantibodies. Cell Rep. 39, 110873 (2022).
Nagele, E. P. et al. Natural IgG autoantibodies are abundant and ubiquitous in human sera, and their number is influenced by age, gender, and disease. PLoS One 8, e60726 (2013).
Cabral-Marques, O. et al. Autoantibodies targeting GPCRs and RAS-related molecules associate with COVID-19 severity. Nat. Commun. 13, 1220 https://doi.org/10.1038/s41467-022-28905-5.
Baiocchi, G. C. et al. Cross-sectional analysis reveals autoantibody signatures associated with COVID-19 severity. J. Med. Virol. 95, e28538 (2023).
Lever, J., Krzywinski, M. & Altman, N. Principal component analysis. Nat. Methods 14, 641–642 (2017).
Liaw, A. & Wiener, M. Classification and Regression by randomForest. https://cogns.northwestern.edu/cbmg/LiawAndWiener2002.pdf (2002).
Huang, S. et al. Applications of Support Vector Machine (SVM) learning in cancer genomics. Cancer Genom. Proteom. 15, 41 LP–41 51 (2018).
Noble, W. S. What is a support vector machine? Nat. Biotechnol. 24, 1565–1567 (2006).
Chen, Y. et al. Aging in COVID-19: Vulnerability, immunity and intervention. Ageing Res. Rev. 65, 101205 (2021).
Manry, J. et al. The risk of COVID-19 death is much greater and age dependent with type I IFN autoantibodies. Proc. Natl. Acad. Sci. USA. 119, e2200413119 (2022).
Xie, Y., Xu, E., Bowe, B. & Al-Aly, Z. Long-term cardiovascular outcomes of COVID-19. Nat. Med. 28, 583–590 (2022).
Bastard, P. et al. Autoantibodies neutralizing type I IFNs are present in ~4% of uninfected individuals over 70 years old and account for ~20% of COVID-19 deaths. Sci. Immunol. 6, eabl4340 (2021).
Zhang, Q. et al. Human genetic and immunological determinants of critical COVID-19 pneumonia. Nature 603, 587–598 (2022).
Bastard, P. et al. Vaccine breakthrough hypoxemic COVID-19 pneumonia in patients with auto-Abs neutralizing type I IFNs. Sci. Immunol. https://doi.org/10.1126/SCIIMMUNOL.ABP8966 (2022).
Cabral-Marques, O. & Riemekasten, G. Functional autoantibodies targeting G protein-coupled receptors in rheumatic diseases. Nat. Rev. Rheumatol. 13, 648–656 (2017).
Cabral-Marques, O. et al. GPCR-specific autoantibody signatures are associated with physiological and pathological immune homeostasis. Nat. Commun. 9, 1–14 (2018).
Bertin, D. et al. Anti-cardiolipin IgG autoantibodies associate with circulating extracellular DNA in severe COVID-19. Sci. Rep. 12, 12523 (2022).
Manoussakis, M. N. et al. High prevalence of anti-cardiolipin and other autoantibodies in a healthy elderly population. Clin. Exp. Immunol. 69, 557–565 (1987).
Njemini, R. et al. The prevalence of autoantibodies in an elderly sub-Saharan African population. Clin. Exp. Immunol. 127, 99–106 (2002).
Beer, J. et al. Impaired immune response drives age-dependent severity of COVID-19. J. Exp. Med. 219, e20220621 (2022).
Neville, C. et al. Thromboembolic risk in patients with high titre anticardiolipin and multiple antiphospholipid antibodies. Thromb. Haemost. 90, 108–115 (2003).
Lambert, M. P. & Gernsheimer, T. B. Clinical updates in adult immune thrombocytopenia. Blood 129, 2829–2835 (2017).
Katsoularis, I. et al. Risks of deep vein thrombosis, pulmonary embolism, and bleeding after covid-19: nationwide self-controlled cases series and matched cohort study. BMJ https://doi.org/10.1136/bmj-2021-069590 (2022).
Quezada-Feijoo, M. et al. Elderly population with COVID-19 and the accuracy of clinical scales and D-dimer for pulmonary embolism: the OCTA-COVID study. J. Clin. Med. 10, 5433 (2021).
Greinacher, A. et al. Anti-platelet factor 4 antibodies causing VITT do not cross-react with SARS-CoV-2 spike protein. Blood 138, 1269–1277 (2021).
Nakamura, T. et al. Detection of anti-GPIbα autoantibodies in a case of immune thrombocytopenia following COVID-19 vaccination. Thromb. Res. 209, 80–83 (2022).
Liu, Q. et al. Anti-PF4 antibodies associated with disease severity in COVID-19. Proc. Natl. Acad. Sci. 119, e2213361119 (2022).
Amendt, T. et al. Autoreactive antibodies control blood glucose by regulating insulin homeostasis. Proc. Natl. Acad. Sci. 119, e2115695119 (2022).
Lutz, H. U., Binder, C. J. & Kaveri, S. Naturally occurring auto-antibodies in homeostasis and disease. Trends Immunol. 30, 43–51 (2009).
Watanabe, M. et al. Anti-cytokine autoantibodies are ubiquitous in healthy individuals. FEBS Lett. 581, 2017–2021 (2007).
Fleg, J. L. & Strait, J. Age-associated changes in cardiovascular structure and function: a fertile milieu for future disease. Heart Fail. Rev. 17, 545–554 (2012).
Thomas, E. T., Guppy, M., Straus, S. E., Bell, K. J. L. & Glasziou, P. Rate of normal lung function decline in ageing adults: a systematic review of prospective cohort studies. BMJ Open 9, e028150 (2019).
de Almeida Chuffa, L. G. et al. Aging whole blood transcriptome reveals candidate genes for SARS-CoV-2-related vascular and immune alterations. J. Mol. Med. 100, 285–301 (2022).
Merad, M. & Martin, J. C. Author correction: pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages. Nat. Rev. Immunol. 20, 448 (2020).
Páez-Franco, J. C. et al. Metabolomics analysis identifies glutamic acid and cystine imbalances in COVID-19 patients without comorbid conditions. Implications on redox homeostasis and COVID-19 pathophysiology. PLoS One 17, 1–17 (2022).
Ludwig, R. J. et al. Mechanisms of Autoantibody-Induced Pathology. Front. Immunol. 8, 603 (2017).
Pacheco, Y. et al. Cytokine and autoantibody clusters interaction in systemic lupus erythematosus. J. Transl. Med. 15, 239 (2017).
Grolleau-Julius, A., Ray, D. & Yung, R. L. The role of epigenetics in aging and autoimmunity. Clin. Rev. Allergy Immunol. 39, 42–50 (2010).
Cao, X. et al. Accelerated biological aging in COVID-19 patients. Nat. Commun. 13, 2135 (2022).
Farris, A. D. & Guthridge, J. M. Overlapping B cell pathways in severe COVID-19 and lupus. Nat. Immunol. 21, 1478–1480 (2020).
Tripathi, U. et al. SARS-CoV-2 causes senescence in human cells and exacerbates the senescence-associated secretory phenotype through TLR-3. Aging (Albany. NY). 13, 21838–21854 (2021).
Bartleson, J. M. et al. SARS-CoV-2, COVID-19 and the aging immune system. Nat. Aging 1, 769–782 (2021).
Collier, D. A. et al. Age-related immune response heterogeneity to SARS-CoV-2 vaccine BNT162b2. Nature 596, 417–422 (2021).
Lynch, S. M., Guo, G., Gibson, D. S., Bjourson, A. J. & Rai, T. S. Role of senescence and aging in SARS-CoV-2 infection and COVID-19 disease. Cells 10, 3367 (2021).
Akbar, A. N. & Gilroy, D. W. Aging immunity may exacerbate COVID-19. Science 369, 256–257 (2020).
Hou, Y. et al. Aging-related cell type-specific pathophysiologic immune responses that exacerbate disease severity in aged COVID-19 patients. Aging Cell 21, e13544 (2022).
Chakravarty, K. K., Gray, R. E. S., Webley, M., Byron, M. A. & Wozniak, J. Prevalence of anticardiolipin antibodies in the elderly British population. Postgrad. Med. J. 67, 358–361 (1991).
Borghi, M. O. et al. Anti-phospholipid antibodies in COVID-19 are different from those detectable in the anti-phospholipid syndrome. Front. Immunol. 11, 584241 (2020).
Silverberg, J. I. et al. Association of varying clinical manifestations and positive anti-SARS-CoV-2 IgG antibodies: a cross-sectional observational study. J. Allergy Clin. Immunol. Pract. 9, 3331–3338.e2 (2021).
Zyskind, I. et al. SARS-CoV-2 seroprevalence and symptom onset in culturally linked orthodox Jewish communities across multiple regions in the United States. JAMA Netw. Open 4, e212816–e212816 (2021).
WHO. COVID-19 Clinical Management: Living Guidance (World Health Organization, 2021).
Khamsi, R. Rogue antibodies could be driving severe COVID-19. Nature 590, 29–31 (2021).
Ehrenfeld, M. et al. Covid-19 and autoimmunity. Autoimmun. Rev. 19, 102597 (2020).
Baiocchi, G. C. et al. Autoantibodies linked to autoimmune diseases associate with COVID-19 outcomes. medRxiv https://doi.org/10.1101/2022.02.17.22271057 (2022).
R Core Team (2018). R: A Language and Environment for Statistical Computing. https://www.gbif.org/tool/81287/r-a-language-and-environment-for-statistical-computing (2015).
CRAN. The R Project for Statistical Computing. https://www.r-project.org/(2023).
RStudio. Open Source & Professional Software for Data Science Teams. https://www.rstudio.com/. (2021).
Wickham, H. ggplot2: Create Elegant Data Visualisations Using the Grammar of Graphics. https://ggplot2.tidyverse.org/ (2023).
Schneider, A., Hommel, G. & Blettner, M. Linear regression analysis. Dtsch. Arztebl. Int. https://doi.org/10.3238/arztebl.2010.0776 (2010).
Faul, F., Erdfelder, E., Lang, A. G. & Buchner, A. G*Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav. Res. Methods 39, 175–191 (2007).
Wickham, H. ggplot2: Elegant Graphics for Data Analysis. https://link.springer.com/book/10.1007/978-0-387-98141-3 (2016).
A, K. rstatix: Pipe-Friendly Framework for Basic Statistical Tests. https://rdrr.io/cran/rstatix/ (2021).
Ringnér, M. What is principal component analysis? Nat. Biotechnol. 2008 263 26, 303–304 (2008).
Lever, J., Krzywinski, M. & Altman, N. Points of significance: principal component analysis. Nature Methods 14, 641–642 (2017).
Sotzny, F. et al. Dysregulated autoantibodies targeting vaso- and immunoregulatory receptors in Post COVID Syndrome correlate with symptom severity. Front. Immunol. 13, 19 (2022).
Braeken, J. & Van Assen, M. A. L. M. An empirical Kaiser criterion. Psychol. Methods 22, 450–466 (2017).
Kassambara, A. & Mundt, F. factoextra: Extract and Visualize the Results of Multivariate Data Analyses. https://CRAN.R-project.org/package=factoextra (2020).
Gu, Z., Eils, R. & Schlesner, M. Complex heatmaps reveal patterns and correlations in multidimensional genomic data. Bioinformatics 32, 2847–2849 (2016).
Gu, Z., Gu, L., Eils, R., Schlesner, M. & Brors, B. circlize Implements and enhances circular visualization in R. Bioinformatics 30, 2811–2812 (2014).
Schimke, L. F. et al. Severe COVID-19 shares a common neutrophil activation signature with other acute inflammatory states. Cells 11, 847 (2022).
Ricciardi, C. et al. Linear discriminant analysis and principal component analysis to predict coronary artery disease. Health Inform. J. 26, 2181–2192 (2020).
Venables, W. N. & Ripley, B. D. Modern Applied Statistics with S. Ripley (Springer, 2002).
Sachs, M. C. plotROC: A tool for plotting ROC curves. J. Stat. Softw. 79, 2 (2017).
Sperandei, S. Understanding logistic regression analysis. Biochem. Med. https://doi.org/10.11613/BM.2014.003 (2014).
Chongsuvivatwong, V. epiDisplay: Epidemiological Data Display Package. https://rdrr.io/cran/epiDisplay/ (2022).
Balduzzi, S., Rücker, G. & Schwarzer, G. How to perform a meta-analysis with R: a practical tutorial. Evid. Based. Ment. Health 22, 153–160 (2019).
Karatzoglou, A., Smola, A. & Hornik, K. Kernel-Based Machine Learning Lab [R package kernlab version 0.9-31]. https://rdrr.io/cran/kernlab/ (2022).
Karatzoglou, A., Hornik, K., Smola, A. & Zeileis, A. kernlab—An S4 package for Kernel methods in R. J. Stat. Softw. 11, 1–20 (2004).
Meyer, D., Dimitriadou, E., Hornik, K., Weingessel, A. & Leisch, F. e1071: Misc Functions of the Department of Statistics, Probability Theory Group (Formerly: E1071), TU Wien. https://rdrr.io/rforge/e1071/ (2021).